Patient and Physician Preferences for Maintenance Treatment in Advanced Non-Small Cell Lung Cancer: Insights into Treatment Selection.

IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Manasee V Shah, Caitlyn T Solem, Anne Liao, Kelly F Bell, Yao Wang, Hongbo Yang, Yan Meng, Mingchen Ye, Umit Tapan
{"title":"Patient and Physician Preferences for Maintenance Treatment in Advanced Non-Small Cell Lung Cancer: Insights into Treatment Selection.","authors":"Manasee V Shah, Caitlyn T Solem, Anne Liao, Kelly F Bell, Yao Wang, Hongbo Yang, Yan Meng, Mingchen Ye, Umit Tapan","doi":"10.1007/s12325-025-03347-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Advanced/metastatic non-small cell lung cancer (a/mNSCLC) is associated with a poor prognosis. Although maintenance therapy after first-line (1L) induction treatment can extend survival, it may also present with drawbacks like risk of certain adverse events (AEs), underscoring the need for shared decision-making between patients and their treating physicians. This study aimed to quantify the extent to which maintenance treatment attributes impact the preferences of patients and physicians after 1L induction therapy for a/mNSCLC.</p><p><strong>Methods: </strong>Eligible patients (aged ≥ 18 years in the UK and US) were diagnosed with a/mNSCLC and had stable disease with or responded to 1L induction therapy. Eligible physicians were licensed oncologists with ≥ 5 years' experience in a/mNSCLC treatment who had treated ≥ 20 such patients in the past year. Surveys assessed the patients' and physicians' perspectives regarding the current treatment landscape of a/mNSCLC, and a discrete choice experiment assessed their preferences regarding treatment characteristics. Data were collected using choice cards, designed to capture treatment attribute preferences including efficacy (progression-free survival [PFS] and overall survival [OS]), chance (risk) of new brain metastasis (BM), and selected AEs.</p><p><strong>Results: </strong>Among 34 UK and 48 US patients, the three most important treatment attributes (in order) were chance of new BM, OS, and risk of severe neutropenia. Among 51 UK and 50 US treating physicians, the 3 most important treatment attributes (in order) were OS, chance of new BM, and PFS.</p><p><strong>Conclusion: </strong>In this real-world survey, OS and chance of new BM were the two most important maintenance treatment attributes for patients with a/mNSCLC and treating physicians. However, the risk of severe neutropenia carried greater relative importance, while PFS carried lesser relative importance, for patients than physicians. These results highlight the differing emphasis placed on attributes by patients and physicians when selecting maintenance treatment.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03347-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Advanced/metastatic non-small cell lung cancer (a/mNSCLC) is associated with a poor prognosis. Although maintenance therapy after first-line (1L) induction treatment can extend survival, it may also present with drawbacks like risk of certain adverse events (AEs), underscoring the need for shared decision-making between patients and their treating physicians. This study aimed to quantify the extent to which maintenance treatment attributes impact the preferences of patients and physicians after 1L induction therapy for a/mNSCLC.

Methods: Eligible patients (aged ≥ 18 years in the UK and US) were diagnosed with a/mNSCLC and had stable disease with or responded to 1L induction therapy. Eligible physicians were licensed oncologists with ≥ 5 years' experience in a/mNSCLC treatment who had treated ≥ 20 such patients in the past year. Surveys assessed the patients' and physicians' perspectives regarding the current treatment landscape of a/mNSCLC, and a discrete choice experiment assessed their preferences regarding treatment characteristics. Data were collected using choice cards, designed to capture treatment attribute preferences including efficacy (progression-free survival [PFS] and overall survival [OS]), chance (risk) of new brain metastasis (BM), and selected AEs.

Results: Among 34 UK and 48 US patients, the three most important treatment attributes (in order) were chance of new BM, OS, and risk of severe neutropenia. Among 51 UK and 50 US treating physicians, the 3 most important treatment attributes (in order) were OS, chance of new BM, and PFS.

Conclusion: In this real-world survey, OS and chance of new BM were the two most important maintenance treatment attributes for patients with a/mNSCLC and treating physicians. However, the risk of severe neutropenia carried greater relative importance, while PFS carried lesser relative importance, for patients than physicians. These results highlight the differing emphasis placed on attributes by patients and physicians when selecting maintenance treatment.

晚期非小细胞肺癌患者和医生对维持治疗的偏好:治疗选择的见解。
晚期/转移性非小细胞肺癌(a/mNSCLC)与不良预后相关。虽然一线诱导治疗(1L)后的维持治疗可以延长生存期,但它也可能存在一些缺点,如某些不良事件(ae)的风险,这强调了患者和治疗医生之间共同决策的必要性。本研究旨在量化维持治疗属性对a/小细胞肺癌1L诱导治疗后患者和医生偏好的影响程度。方法:符合条件的患者(英国和美国年龄≥18岁)被诊断为a/mNSCLC,病情稳定或对1L诱导治疗有反应。符合条件的医生是具有≥5年a/mNSCLC治疗经验且在过去一年中治疗过≥20例此类患者的执业肿瘤学家。调查评估了患者和医生对a/mNSCLC当前治疗前景的看法,离散选择实验评估了他们对治疗特征的偏好。使用选择卡收集数据,旨在捕获治疗属性偏好,包括疗效(无进展生存期[PFS]和总生存期[OS]),新脑转移(BM)的机会(风险)和选定的ae。结果:在34名英国和48名美国患者中,三个最重要的治疗属性(按顺序)是新BM的机会,OS和严重中性粒细胞减少的风险。在51名英国和50名美国治疗医生中,3个最重要的治疗属性(按顺序)是OS,新BM的机会和PFS。结论:在这项真实世界的调查中,对于a/mNSCLC患者和治疗医生来说,OS和新脑转移的机会是两个最重要的维持治疗属性。然而,对于患者而言,严重中性粒细胞减少的风险相对重要,而PFS相对不那么重要。这些结果突出了患者和医生在选择维持治疗时对属性的不同重视。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Therapy
Advances in Therapy 医学-药学
CiteScore
7.20
自引率
2.60%
发文量
353
审稿时长
6-12 weeks
期刊介绍: Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信